Italia markets open in 3 hours 48 minutes

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
9,88-0,21 (-2,08%)
Alla chiusura: 04:00PM EDT
9,88 0,00 (0,00%)
Dopo ore: 05:23PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente10,09
Aperto10,15
Denaro9,87 x 1200
Lettera10,66 x 1200
Min-Max giorno9,72 - 10,42
Intervallo di 52 settimane1,45 - 11,44
Volume287.034
Media Volume299.571
Capitalizzazione489,221M
Beta (5 anni mensile)-1,05
Rapporto PE (ttm)N/D
EPS (ttm)-2,26
Prossima data utili24 mar 2023 - 08 apr 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A12,60
  • GlobeNewswire

    Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences

    Completes enrollment in Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) as a treatment for NASH with top-line results expected in third quarter of 2023 On track to initiate U.S. clinical trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at a major upcoming oncology conference IND-enabling activities for TERN-601 (oral GLP-1R agonist) ongoing; on track to initiate first-in-human clinical t

  • GlobeNewswire

    Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference

    FOSTER CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023 at 10:10 a.m.

  • GlobeNewswire

    Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference

    FOSTER CITY, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 2:30 p.m. ET